Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of BI 10773 as add-on to Insulin Regimen in Patients With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~1. Diagnosis of T2DM prior to informed consent~2. Male and female patients on diet and exercise regimen who are pre-treated with multiple daily injections (MDI) of insulin alone or in combination with immediate or extended release metformin~3. Stable metformin therapy: daily dose \>=1500 mg/day or maximum tolerated dose~4. HbA1c \>=7.5% and \<=10% at screening~Exclusion criteria:~1. Uncontrolled hyperglycemia with a glucose level \>240 mg/dl (\>13.3 mmol/L) after an overnight fast during placebo run-in~2. Any contraindications to metformin according to the local label~3. Acute coronary syndrome, stroke or TIA within 3 months prior to informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BI 10773 low dose (Type: EXPERIMENTAL): BI 10773 low dose once daily
- BI 10773 high dose (Type: EXPERIMENTAL): BI 10733 high dose once daily
- Placebo (Type: PLACEBO_COMPARATOR): Placebo tablets matching BI 10773

Based on this trial design, predict the completion outcome and termination type (if applicable).